Key Highlights
- Seismic Therapeutic, Inc., a machine learning immunology company, announces a $121 million Series B financing, led by Bessemer Venture Partners.
- Funding will advance Phase 1 trials for two lead programs: a pan-IgG protease enzyme candidate (S-1117) and a PD-1 agonist antibody candidate (S-4321).
- The Series B financing also aims to expand the company’s pipeline and enhance its machine learning-enabled IMPACT platform for biologics drug discovery.
- Andrew Hedin, MBA, from Bessemer Venture Partners, will join Seismic’s board of directors.
- Jo Viney, Ph.D., Founder, President, and CEO of Seismic Therapeutic, highlights the company’s vision for a new era in immunology drug development.
Source: Business Wire
Notable Quotes
- “Seismic has made impressive achievements in a short time integrating the power of machine learning with its deep drug development expertise to create two differentiated lead programs. each offering a compelling opportunity to address unmet medical needs in autoimmune diseases in a new way.” – Andrew Hedin, MBA, Partner at Bessemer Venture Partners
- “This financing enables us to continue our momentum and advance both of our exciting lead programs into the clinic. We believe the time is right to harness advances in machine learning to discover the next generation of biologics drugs to improve the lives of patients with autoimmune diseases.” – Jo Viney, Ph.D., Founder, President, and CEO at Seismic Therapeutic
SoH's Take
The substantial Series B funding raised by Seismic Therapeutic is a testament to the growing confidence in machine learning’s role in drug development. This move marks a significant step in the biotechnology sector, especially in the realm of immunology. The focus on leveraging machine learning for precise, efficient drug discovery and development reflects a broader industry trend towards integrating advanced technologies in healthcare. Seismic’s commitment to developing innovative treatments for autoimmune diseases through its IMPACT platform is a clear indication of the potential machine learning holds in revolutionizing the way biologics are discovered and developed. As the company advances its lead programs into clinical trials, it is poised to set new benchmarks in the field, potentially leading to more effective and targeted therapies for autoimmune conditions.
